— Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes unanimously that price for Spinraza is too high to align fairly with these benefits, and urges fair pricing for emerging gene therapy Zolgensma to support sustainable access to innovation — BOSTON, April 3, 2019 – The Institute for Clinical […]
Read More
04/03/2019
– Open input period now open until August 17th – Boston – July 31, 2018 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of AVXS-101 (Novartis) and nusinersen (Spinraza®, Biogen) for treatment of spinal muscular atrophy (SMA). ICER’s report is set to be reviewed during a […]
Read More
08/01/2018
— Collaborative project with NICE and CADTH leads to important adaptations for ICER’s methods including creation of optimistic and conservative benefit scenarios; new dimensions of benefits and contextual considerations for voting; and two new scenarios that display the potential impact on pricing that would result from sharing the savings of downstream cost offsets between society […]
Read More
11/12/2019
— Appraisal committee vote reveals differences in judgments on value given pricing far above traditional cost-effectiveness levels — –Policy recommendations call attention to the growing stream of treatments for rare disorders that cannot all be priced at similar levels without threatening the financial sustainability of the health system — BOSTON, February 14, 2018-The Institute […]
Read More
02/14/2018
Public Comments
Closed